scholarly journals Abnormal involuntary movement scale in tardive dyskinesia: Minimal clinically important difference

2019 ◽  
Vol 34 (8) ◽  
pp. 1203-1209 ◽  
Author(s):  
Mark Stacy ◽  
Martha Sajatovic ◽  
John M. Kane ◽  
Andrew J. Cutler ◽  
Grace S. Liang ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Minimal Clinically Important Difference ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Clinically Important Difference

scholarly journals Minimal Clinically Important Difference in AIMS Score Based on CGIC and PGIC in Patients With Tardive Dyskinesia Treated With Deutetrabenazine

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 159-159
Author(s):  
Hadas Barkay ◽  
Robert A. Hauser ◽  
Amanda Wilhelm ◽  
Maria Wieman ◽  
Mark Forrest Gordon ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Minimal Clinically Important Difference ◽  
Involuntary Movement ◽  
Treatment Success ◽  
Meaningful Improvement ◽  
Clinically Important Difference ◽  
Pharmaceutical Industries ◽  
The Difference ◽  
Global Impression Of Change ◽  
Treatment Improvement

AbstractBackgroundDeutetrabenazine is FDA approved for tardive dyskinesia (TD) based on two 12-week, placebo-controlled studies evaluating safety and efficacy in patients with baseline Abnormal Involuntary Movement Scale (AIMS) score ≥6. Deutetrabenazine reduced overall AIMS scores compared with placebo in ARM-TD (–3.0 vs –1.6, P=0.019) and AIM-TD (24 mg/day, –3.2 vs –1.4, P=0.003; 36 mg/day, –3.3 vs –1.4, P=0.001). This analysis assessed Minimal Clinically Important Difference (MCID) in AIMS score in patients with TD treated with deutetrabenazine.MethodsMCID is the smallest change from baseline in AIMS score that is meaningful for patients. MCID analyses were performed based on Patient Global Impression of Change (PGIC) and Clinical Global Impression of Change (CGIC) as anchors described by Hauser et al., where MCID is the difference between patients treated with deutetrabenazine who were minimally improved and patients treated with placebo who were unchanged. Additional MCID definitions were explored: difference between patients who demonstrated treatment improvement versus those who did not (Method 2); difference between patients who demonstrated treatment success versus those who did not (Method 3).Results295 patients were analyzed. Based on PGIC, the suggested MCID was –2.8. Results were similar for Method 2 (75% of patients had treatment improvement; MCID = –2.8) and Method 3 (38% of patients had treatment success; MCID = –2.6). Based on CGIC, the suggested MCID was –2.6. Results were similar for Method 2 (76% of patients had treatment improvement; MCID = –2.8) and Method 3 (41% of patients had treatment success; MCID = –3.0). Therefore, the suggested MCID for deutetrabenazine is –3.ConclusionsThe MCID for change in AIMS score based on PGIC and CGIC for deutetrabenazine was –3 regardless of the analytical method. Findings suggest an AIMS score reduction of ~3 is associated with clinically meaningful improvement in TD symptoms.FundingTeva Pharmaceutical Industries Ltd., Petach Tikva, Israel

Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia

2005 ◽  
Vol 77 (2-3) ◽  
pp. 119-128 ◽  
Author(s):  
Georges M. Gharabawi ◽  
Cynthia A. Bossie ◽  
Robert A. Lasser ◽  
Ibrahim Turkoz ◽  
Stephen Rodriguez ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Rating Scale ◽  
Extrapyramidal Symptom ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Symptom Rating

Correlates of the Abnormal Involuntary Movement Scale in Veterans With Tardive Dyskinesia

2020 ◽  
Vol 40 (4) ◽  
pp. 373-380 ◽  
Author(s):  
Stanley N. Caroff ◽  
Shirley H. Leong ◽  
Christopher B. Roberts ◽  
Rosalind M. Berkowitz ◽  
E. Cabrina Campbell
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

Orofacial Dyskinesia, Cognitive Function and Medication

1986 ◽  
Vol 149 (2) ◽  
pp. 216-220 ◽  
Author(s):  
Philip Thomas ◽  
Ralph McGuire
Keyword(s):  
Regression Analysis ◽  
Cognitive Function ◽  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
The Other ◽  
Orofacial Dyskinesia ◽  
Duration Of Treatment ◽  
Delayed Recall ◽  
Abnormal Involuntary Movement Scale ◽  
Abnormal Movements

The presence of tardive dyskinesia in a sample of 43 patients with schizophrenia and 37 psychopaths who had been hospitalised for many years and exposed to large amounts of medication was assessed while testing their cognitive function. Subjects who showed no evidence of abnormal movements performed significantly better on the test of delayed recall, but there were no differences in performance on any of the other tests of cognitive function used. Multiple regression analysis revealed that age and the total lifetime dose of neuroleptic medication received (in chlorpromazine equivalents) were the only variables to predict the Abnormal Involuntary Movement Scale score, although a large amount of variance in this variable was unaccounted for. The duration of treatment with neuroleptics did not predict AIMS score.

scholarly journals Using Item 8 of the Abnormal Involuntary Movement Scale (AIMS) to Assess Improvement in Patients with Tardive Dyskinesia

CNS Spectrums ◽  
2021 ◽  
Vol 26 (2) ◽  
pp. 152-152
Author(s):  
Leslie Citrome ◽  
Leslie Lundt ◽  
Chirag Shah ◽  
Tara Carmack
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Real Life ◽  
Meaningful Improvement ◽  
Once Daily ◽  
Abnormal Involuntary Movement Scale ◽  
Clinical Measure ◽  
Long Term Study ◽  
Using Data ◽  
Post Hoc

AbstractObjectiveThe Abnormal Involuntary Movement Scale (AIMS) total score (sum of items 1–7) is usually the primary efficacy measure in tardive dyskinesia (TD) clinical trials. However, item 8 of the AIMS (clinician’s global impression of severity) might also be an appropriate assessment in real-life healthcare settings. To explore the potential of item 8 as a clinical measure, post hoc analyses were conducted using data from a long-term study of valbenazine, an approved TD medication.MethodsIn KINECT 4 (NCT02405091), adults with TD received once-daily valbenazine (40 or 80 mg) for 48 weeks. Analyses included two sets of AIMS item 8 scores: based on investigators ratings of item 8 using protocol-defined descriptors; and based on investigators highest scores from items 1–7 (analyzed post hoc). Shift analyses included an improvement from score =3 at baseline (moderate or severe) to score =2 at Week 48 (none to mild).ResultsAt baseline in all participants (N=163), AIMS item 8 mean scores were 3.2 (protocol) and 3.3 (post hoc). In participants with a score =3 at baseline per investigators ratings using protocol-defined descriptors, 95.9% [94/98] shifted to a score =2 by Week 48. A similar result (93.9% [93/99]) was found when item 8 was based on investigators highest scores from items 1–7.ConclusionShift analyses using AIMS item 8 scores indicated that most participants in KINECT 4 had a clinically meaningful improvement after 48 weeks of once-daily treatment with valbenazine. AIMS item 8 may be an appropriate clinical measure for assessing changes in TD severity.FundingNeurocrine Biosciences, Inc.

Assessment of Tardive Dyskinesia Using the Abnormal Involuntary Movement Scale

1985 ◽  
Vol 173 (6) ◽  
pp. 353-357 ◽  
Author(s):  
RICHARD D. LANE ◽  
WILLIAM M. GLAZER ◽  
THOMAS E. HANSEN ◽  
WILLIAM H. BERMAN ◽  
STEPHEN I. KRAMER
Keyword(s):  
Tardive Dyskinesia ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale

scholarly journals Improvement of Tardive Dyskinesia during Mindfulness Meditation

2021 ◽  
Vol 13 (3) ◽  
pp. 439-444
Author(s):  
Maria Angela Santoro ◽  
Isolde English ◽  
Idil Sezer ◽  
Mickael Amagat ◽  
Frank Ly ◽  
...  
Keyword(s):  
Tardive Dyskinesia ◽  
Cognitive Therapy ◽  
Stress Reduction ◽  
Therapeutic Approach ◽  
First Generation ◽  
Mindfulness Meditation ◽  
Involuntary Movement ◽  
Abnormal Involuntary Movement Scale ◽  
Mindfulness Based Stress Reduction

Background: We report the case of a patient presenting with orofacial tardive dyskinesia (TD), following administration of a first-generation antipsychotic (Loxapine). Intervention: Four weeks of repeated sessions of mindfulness-based cognitive therapy (MBCT) and mindfulness-based stress reduction (MBSR) protocols were administered, with TD hetero-quantified before and during each session via the Abnormal Involuntary Movement Scale (AIMS). Results: The dyskinesia ameliorated quantitatively and qualitatively (1) during each session, and (2) at resting conditions in the long term. During some sessions, after which patients’ compliance was auto-evaluated as maximal, complete arrest of the TD was observed. Hypothesis and Conclusion: We suggest mindfulness meditation as a novel adjunctive therapeutic approach for tardive dyskinesia, and invite for further clinical and neurological investigations.

Sign in / Sign up

Export Citation Format

Share Document